$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000147929021000057 Filed on February 25, 2021

Income Statement

Concept	2019 Q4	2018	2017 Q4
Revenue	$89.00K	$3.729M	$37.00K
YoY Change	-81.72%	1323.28%	-50.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$18.77M	$53.86M	$11.89M
YoY Change	40.49%	44.03%	67.46%
% of Gross Profit
Research & Development	$27.49M	$92.50M	$21.00M
YoY Change	7.68%	15.11%	67.6%
% of Gross Profit
Depreciation & Amortization	$760.0K	$1.726M	$370.0K
YoY Change	58.33%	17.57%	-2.63%
% of Gross Profit
Operating Expenses	$46.26M	$146.4M	$32.89M
YoY Change	18.95%	21.28%	67.55%
Operating Profit	-$46.17M	-$142.6M
YoY Change	20.2%	18.44%
Interest Expense	$980.0K	$44.00K	$10.00K
YoY Change	5.38%	-90.37%	-200.0%
% of Operating Profit
Other Income/Expense, Net	-$130.0K	-$773.0K	-$140.0K
YoY Change	-13.33%	47.24%	7.69%
Pretax Income	-$45.33M	-$139.6M	-$35.91M
YoY Change	20.49%	17.95%	33.99%
Income Tax	$0.00	$3.000M	$0.00
% Of Pretax Income
Net Earnings	-$45.33M	-$142.6M	-$40.62M
YoY Change	11.6%	18.23%	51.54%
Net Earnings / Revenue	-50928.09%	-3823.22%	-109772.97%
Basic Earnings Per Share
Diluted Earnings Per Share	-$993.0K	-$3.942M	-$1.139M
COMMON SHARES
Basic Shares Outstanding	45.11M shares		30.93M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$290.1M	$175.8M	$282.9M
YoY Change	65.02%	-37.86%	52.51%
Cash & Equivalents	$171.2M	$73.30M	$282.9M
Short-Term Investments	$119.0M	$102.6M	$0.00
Other Short-Term Assets	$6.500M	$5.100M	$444.0K
YoY Change	27.45%	131.82%	172.39%
Inventory	$0.00
Prepaid Expenses			$1.823M
Receivables	$0.00	$27.00M	$48.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$296.6M	$207.9M	$285.2M
YoY Change	42.65%	-27.1%	48.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.76M	$14.40M	$9.250M
YoY Change	2.12%	54.84%	-12.61%
Goodwill	$0.00
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.669M	$4.000M	$658.0K
YoY Change	-48.6%	233.33%	31.6%
Total Long-Term Assets	$43.69M	$18.40M	$10.49M
YoY Change	137.08%	75.24%	-10.09%
TOTAL ASSETS
Total Short-Term Assets	$296.6M	$207.9M	$285.2M
Total Long-Term Assets	$43.69M	$18.40M	$10.49M
Total Assets	$340.3M	$226.3M	$295.7M
YoY Change	50.34%	-23.47%	44.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.010M	$8.400M	$6.805M
YoY Change	-5.03%	23.53%	81.27%
Accrued Expenses	$18.64M	$14.40M	$12.23M
YoY Change	24.67%	25.22%	-1.55%
Deferred Revenue	$7.911M		$0.00
YoY Change	-7.88%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$1.900M
YoY Change		-100.0%	-45.71%
Total Short-Term Liabilities	$40.98M	$32.00M	$20.90M
YoY Change	28.18%	53.11%	6.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$73.80M	$48.80M	$0.00
YoY Change	51.23%	713.33%	-100.0%
Total Long-Term Liabilities	$73.80M	$48.80M	$0.00
YoY Change	51.23%	713.33%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.98M	$32.00M	$20.90M
Total Long-Term Liabilities	$73.80M	$48.80M	$0.00
Total Liabilities	$114.8M	$80.70M	$26.85M
YoY Change	42.21%	200.0%	-1.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$844.2M		-$542.2M
YoY Change	23.28%		28.61%
Common Stock	$1.070B		$811.0M
YoY Change	28.82%		35.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$225.5M	$145.6M	$268.8M
YoY Change
Total Liabilities & Shareholders Equity	$340.3M	$226.3M	$295.7M
YoY Change	50.34%	-23.47%	44.7%

Cashflow Statement

Concept	2019 Q4	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$45.33M	-$142.6M	-$40.62M
YoY Change	11.6%	18.23%	51.54%
Depreciation, Depletion And Amortization	$760.0K	$1.726M	$370.0K
YoY Change	58.33%	17.57%	-2.63%
Cash From Operating Activities	-$33.51M	-$104.2M	-$28.39M
YoY Change	7.61%	9.34%	110.76%
INVESTING ACTIVITIES
Capital Expenditures	-$290.0K	$6.991M	-$490.0K
YoY Change	-82.1%	176.87%	-5.77%
Acquisitions
YoY Change
Other Investing Activities	$31.21M	-$100.0M	$96.79M
YoY Change	-48.6%	-182.46%	-284.96%
Cash From Investing Activities	$30.92M	-$107.0M	$96.30M
YoY Change	-47.68%	-190.1%	-282.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	114.8M	$1.782M	158.7M
YoY Change	71668.75%	-99.09%	-23780.6%
NET CHANGE
Cash From Operating Activities	-33.51M	-$104.2M	-28.39M
Cash From Investing Activities	30.92M	-$107.0M	96.30M
Cash From Financing Activities	114.8M	$1.782M	158.7M
Net Change In Cash	112.2M	-$209.5M	226.6M
YoY Change	299.15%	-195.49%	-438.27%
FREE CASH FLOW
Cash From Operating Activities	-$33.51M	-$104.2M	-$28.39M
Capital Expenditures	-$290.0K	$6.991M	-$490.0K
Free Cash Flow	-$33.22M	-$111.2M	-$27.90M
YoY Change	12.53%	13.66%	115.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2017	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201807Member
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36297
CY2020	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0551645
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	1222 Demonbreun Street, Suite 1001
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Nashville
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37203
CY2020	dei	City Area Code CityAreaCode	615
CY2020	dei	Local Phone Number LocalPhoneNumber	724-7755
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020	dei	Trading Symbol TradingSymbol	RVNC
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1400000000	USD
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71377818	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	333558000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171160000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	102947000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	118955000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1829000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	5876000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5793000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6487000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	450003000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	296602000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17499000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14755000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	146964000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	0	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	71343000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29632000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26531000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3445000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	730000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1334000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1669000	USD
CY2019Q4	us-gaap	Assets Assets	340287000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12657000	USD
CY2020Q4	us-gaap	Assets Assets	720220000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8010000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32938000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18636000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7851000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7911000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4437000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3470000	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3081000	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2952000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	60964000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40979000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	180526000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	77294000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	47948000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27146000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25870000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	345930000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	114797000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69178666	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69178666	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52374735	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52374735	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	69000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	52000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1500514000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1069639000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1126293000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-844204000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	374290000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	225490000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	720220000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	340287000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15325000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3729000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	151846000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	62011000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53863000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	125795000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	102861000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92500000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	6077000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	0	USD
CY2018	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	0	USD
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	288487000	USD
CY2019	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	164872000	USD
CY2018	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	146363000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-273162000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-164459000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-142634000	USD
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4322000	USD
CY2019	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	5532000	USD
CY2018	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4023000	USD
CY2020	us-gaap	Interest Expense InterestExpense	15148000	USD
CY2019	us-gaap	Interest Expense InterestExpense	0	USD
CY2018	us-gaap	Interest Expense InterestExpense	44000	USD
CY2020	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-129000	USD
CY2019	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-199000	USD
CY2018	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-140000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-592000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-303000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-773000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-284709000	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-159429000	USD
CY2018	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-139568000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2620000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-282089000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-159429000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-142568000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-159418000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-142576000	USD
CY2020	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-282089000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-282092000	USD
CY2019	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-159429000	USD
CY2018	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-142568000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.86
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.67
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.94
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58009162	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43460804	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36171582	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	268845000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4527000	USD
CY2018	rvnc	Stock Issued During Period Value Restricted Stock Award Net Of Shares Repurchased StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased	0	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	188090000	USD
CY2020	rvnc	Stock Issued During Period Value Restricted Stock Award Net Of Shares Repurchased StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased	0	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	68156000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	765000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2212000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16273000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-142568000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	145622000	USD
CY2019	rvnc	Stock Issued During Period Value New Issues Follow On Offering StockIssuedDuringPeriodValueNewIssuesFollowOnOffering	211200000	USD
CY2019	rvnc	Stock Issued During Period Value Restricted Stock Award Net Of Shares Repurchased StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased	0	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10605000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	818000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	119000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1378000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17922000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-159429000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	225490000	USD
CY2020	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	43400000	USD
CY2020	rvnc	Stock Issued During Period Value New Issues Follow On Offering StockIssuedDuringPeriodValueNewIssuesFollowOnOffering	15537000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5248000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1644000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	108510000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	8441000	USD
CY2020	rvnc	Adjustment To Additional Paid In Capital Capped Call Transactions AdjustmentToAdditionalPaidInCapitalCappedCallTransactions	28865000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37613000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-282089000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	374290000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-282089000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-159429000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-142568000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	36453000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	17922000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	16273000	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	11184000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	10726000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2020	us-gaap	Depreciation Depreciation	10250000	USD
CY2019	us-gaap	Depreciation Depreciation	2909000	USD
CY2018	us-gaap	Depreciation Depreciation	1726000	USD
CY2020	rvnc	Non Cash Income Tax Expense Benefit NonCashIncomeTaxExpenseBenefit	-2720000	USD
CY2019	rvnc	Non Cash Income Tax Expense Benefit NonCashIncomeTaxExpenseBenefit	0	USD
CY2018	rvnc	Non Cash Income Tax Expense Benefit NonCashIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1423000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2637000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1103000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	8000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1466000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	907000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-810000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-175000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1736000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27000000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26952000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5876000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-912000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1377000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2911000	USD
CY2020	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	3101000	USD
CY2019	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	1868000	USD
CY2018	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	0	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-335000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1578000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1871000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4425000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-360000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1691000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	13484000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3565000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1488000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	29286000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4587000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	51272000	USD
CY2020	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	2243000	USD
CY2019	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	1147000	USD
CY2018	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-178502000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106161000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-104246000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	259500000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	317000000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	146000000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	16969000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	67435000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	259304000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3238000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6991000	USD
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4098000	USD
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	331362000	USD
CY2018	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	314911000	USD
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	818000	USD
CY2019	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	118000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	100000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	8000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1541000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12131000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17592000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107026000	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	287500000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	68367000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10870000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	15581000	USD
CY2019	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	211970000	USD
CY2018	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6892000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	937000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5292000	USD
CY2020	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28865000	USD
CY2019	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9190000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8441000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1378000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2212000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	360000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	742000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	366000	USD
CY2020	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	0	USD
CY2019	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	0	USD
CY2018	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	932000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	331484000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	221657000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-209490000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171890000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1782000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	165113000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	97904000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73986000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283476000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	337003000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171890000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73986000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2530000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	16000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	100000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020Q4	rvnc	Working Capital Surplus WorkingCapitalSurplus	389000000.0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	188090000	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2018	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	43400000	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2020	rvnc	Internally Developed Software Capitalized From Stock Based Compensation InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation	1160000	USD
CY2019	rvnc	Internally Developed Software Capitalized From Stock Based Compensation InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation	0	USD
CY2018	rvnc	Internally Developed Software Capitalized From Stock Based Compensation InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation	0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	904000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	619000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	642000	USD
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	188000	USD
CY2019	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	293000	USD
CY2018	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	354000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-282100000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, the fair value of assets and liabilities assumed in business combinations, incremental borrowing rate used to measure operating lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, period of benefit associated with deferred costs, useful lives of customer contracts, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals including clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration in asset acquisitions, and income taxes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, clinical trials, product launch timing, and commercial activities. As of the date of issuance of these consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our consolidated financial statements.</span></div>
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1100000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	436500000	USD
CY2020	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to a concentration of credit risk consist of short-term investments. Under our investment policy, we limit our credit exposure by investing in highly liquid funds and debt obligations of the U.S. government and its agencies with high credit quality. Our cash, cash equivalents, and short-term investments are held in the U.S. Such deposits may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash, cash equivalents, and short-term investments.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our product revenue was related to sales through one third-party distributor.</span></div>
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	700000	USD
CY2019Q4	rvnc	Restricted Cash Minimum Balance RestrictedCashMinimumBalance	500000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3400000	USD
CY2020Q4	rvnc	Restricted Cash Minimum Balance RestrictedCashMinimumBalance	500000	USD
CY2019Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	3500000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15325000	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	31000000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2018	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2020Q4	rvnc	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Prepaid Expenses And Other Current Assets BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesAndOtherCurrentAssets	200000	USD
CY2020Q4	rvnc	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Goodwill BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill	2500000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	380576000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	78534000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7191000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	71343000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7200000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	13983000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	13925000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	102947000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	118955000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	380576000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	282683000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	282686000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	380576000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	282686000	USD
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	11200000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	13925000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8137000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3267000	USD
CY2020Q4	rvnc	Accrued Inventory Current AccruedInventoryCurrent	1796000	USD
CY2019Q4	rvnc	Accrued Inventory Current AccruedInventoryCurrent	0	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1472000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	206000	USD
CY2020Q4	rvnc	Accrued Nonrecurring Milestone Payment Current Portion AccruedNonrecurringMilestonePaymentCurrentPortion	1000000	USD
CY2019Q4	rvnc	Accrued Nonrecurring Milestone Payment Current Portion AccruedNonrecurringMilestonePaymentCurrentPortion	1000000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32938000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18636000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31621000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19491000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1906000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55143000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	5900000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17374000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7933000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5683000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4751000	USD
CY2020Q4	rvnc	Accruals Clinical Trials Current AccrualsClinicalTrialsCurrent	3726000	USD
CY2019Q4	rvnc	Accruals Clinical Trials Current AccrualsClinicalTrialsCurrent	4746000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1887000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	36990000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16866000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17499000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14755000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	5932000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	5618000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	912000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	1184000	USD
CY2020	us-gaap	Lease Cost LeaseCost	6844000	USD
CY2019	us-gaap	Lease Cost LeaseCost	6802000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7649000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6613000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6741000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6952000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7165000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	8003000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	43123000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11540000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	31583000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.106
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.120
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	6790000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	6339000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5683000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3890000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P150M
CY2020	rvnc	Lessee Operating Lease Lease Not Yet Commenced Number Of Option To Extend LesseeOperatingLeaseLeaseNotYetCommencedNumberOfOptionToExtend	1	option_to_extend_lease_term
CY2020Q4	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Renewal Term1 LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1	P7Y
CY2020Q4	rvnc	Lessee Operating Lease Lease Not Yet Commenced Amount LesseeOperatingLeaseLeaseNotYetCommencedAmount	22900000	USD
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4416000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10393000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	333000	USD
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	15142000	USD
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28900000	USD
CY2020Q1	rvnc	Capped Calls Price Cap CappedCallsPriceCap	48.88	shares
CY2020Q1	rvnc	Capped Calls Premium Percentage Over Sale Price CappedCallsPremiumPercentageOverSalePrice	1
CY2020Q1	rvnc	Capped Calls Number Of Shares Subject To Antidilution Adjustments CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments	8900000	shares
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28900000	USD
CY2020	rvnc	Numberof Equity Compensation Plans NumberofEquityCompensationPlans	4	equity_compensation_plan
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3210400	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.41
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1136650	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	28.30
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.35
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	293100	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	15.45
CY2018Q4	rvnc	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedAggregateIntrinsicValue	1519000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	448617	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	25.59
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3605333	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.66
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1976750	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.53
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.29
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10135	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.76
CY2019Q4	rvnc	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedAggregateIntrinsicValue	45000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	837332	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	22.40
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4734616	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.34
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1037675	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.71
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.10
CY2020	rvnc	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Acquisition ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisition	801600	shares
CY2020	rvnc	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Acquisition Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice	2.20
CY2020	rvnc	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Acquisition Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageGrantDateFairValue	21.36
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	624832	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.40
CY2020Q4	rvnc	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedAggregateIntrinsicValue	12460000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	232315	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.94
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5716744	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.72
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	58440000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3287740	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	20.51
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y7M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	29057000	USD
CY2020Q4	rvnc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Total Unrecognized Compensation Cost EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedTotalUnrecognizedCompensationCost	88808000	USD
CY2020	rvnc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Total Unrecognized Compensation Cost SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1TotalUnrecognizedCompensationCost	P2Y6M
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.78
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.00
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	13.06
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	18.10
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36453000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17922000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16273000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	27418000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y7M6D
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	18487000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y10M24D
CY2020Q4	rvnc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Restricted Stock Awards EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedRestrictedStockAwards	50616000	USD
CY2020	rvnc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Restricted Stock Awards SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1RestrictedStockAwards	P2Y8M12D
CY2019Q4	rvnc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Restricted Stock Awards EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedRestrictedStockAwards	11891000	USD
CY2019	rvnc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Restricted Stock Awards SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1RestrictedStockAwards	P2Y3M18D
CY2020Q4	rvnc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Performance Stock Awards EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPerformanceStockAwards	10774000	USD
CY2020	rvnc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Performance Stock Awards SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1PerformanceStockAwards	P1Y
CY2019Q4	rvnc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Performance Stock Awards EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPerformanceStockAwards	8839000	USD
CY2019	rvnc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Performance Stock Awards SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1PerformanceStockAwards	P2Y4M24D
CY2019Q4	rvnc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Total Unrecognized Compensation Cost EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedTotalUnrecognizedCompensationCost	39217000	USD
CY2019	rvnc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Total Unrecognized Compensation Cost SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1TotalUnrecognizedCompensationCost	P2Y7M6D
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	34113	shares
CY2020Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	326200000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	108000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	100000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3000000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	100000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3000000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1712000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1008000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2720000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2620000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-59789000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-33480000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-29309000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3903000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4723000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4064000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1004000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1429000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	36379000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	57883000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	42902000	USD
CY2020	rvnc	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensation	3164000	USD
CY2019	rvnc	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensation	363000	USD
CY2018	rvnc	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensation	319000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	950000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	32000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-472000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	79000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2370000	USD
CY2020	rvnc	Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount	0	USD
CY2019	rvnc	Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount	0	USD
CY2018	rvnc	Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount	-14008000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	5154000	USD
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-2620000	USD
CY2019	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2018	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	3000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	246510000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	184879000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	21939000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	17449000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	12579000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	10703000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9575000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6241000	USD
CY2020Q4	rvnc	Deferred Tax Asset Operating Lease Liabilities DeferredTaxAssetOperatingLeaseLiabilities	7381000	USD
CY2019Q4	rvnc	Deferred Tax Asset Operating Lease Liabilities DeferredTaxAssetOperatingLeaseLiabilities	6174000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2873000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1537000	USD
CY2020Q4	rvnc	Deferred Tax Assets Fixedandintangibleassets DeferredTaxAssetsFixedandintangibleassets	348000	USD
CY2019Q4	rvnc	Deferred Tax Assets Fixedandintangibleassets DeferredTaxAssetsFixedandintangibleassets	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	19000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2856000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	301231000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	229858000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	267292000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	224222000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	33939000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5636000	USD
CY2020Q4	rvnc	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	23769000	USD
CY2019Q4	rvnc	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6926000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	5583000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3244000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	USD
CY2020Q4	rvnc	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	0	USD
CY2019Q4	rvnc	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	53000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	43100000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	54700000	USD
CY2020Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5698000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4200000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2577000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	235000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1233000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	333000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	333000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1498000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1290000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7166000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5698000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4200000	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	8000000.0	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	30000000.0	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	30000000.0	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	30000000.0	USD
CY2020Q4	us-gaap	Significant Supply Commitment Remaining Minimum Amount Committed SignificantSupplyCommitmentRemainingMinimumAmountCommitted	3300000	USD
CY2020Q4	rvnc	Significant Supply Commitment Additional Amount Committed SignificantSupplyCommitmentAdditionalAmountCommitted	1200000	USD
CY2020	rvnc	Payment Arrangement Renewal Term PaymentArrangementRenewalTerm	P1Y
CY2020	rvnc	Indemnification Liability Recordedduring Period IndemnificationLiabilityRecordedduringPeriod	0	USD
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15325000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	413000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3729000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-273162000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-164459000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-142634000	USD

Files In Submission

Name	View Source	Status
0001479290-21-000057-index-headers.html	Edgar Link	pending
0001479290-21-000057-index.html	Edgar Link	pending
0001479290-21-000057.txt	Edgar Link	pending
0001479290-21-000057-xbrl.zip	Edgar Link	pending
ex1011_rsax2014inxfy2010-k.htm	Edgar Link	pending
ex1027_managementbonusplan.htm	Edgar Link	pending
ex1031_amendementabpsxfy20.htm	Edgar Link	pending
ex1035_amendmenttofosunagr.htm	Edgar Link	pending
ex106_rsax2014eipxfy2010-k.htm	Edgar Link	pending
ex44_descriptionofcommonst.htm	Edgar Link	pending
ex_1020xamendmenttonashvil.htm	Edgar Link	pending
ex_211listofsubsidiariesxf.htm	Edgar Link	pending
ex_231xpublicaccountingfir.htm	Edgar Link	pending
ex_311xcertificationofpeox.htm	Edgar Link	pending
ex_312xertificationofpfoxf.htm	Edgar Link	pending
ex_321xcertificationofpeox.htm	Edgar Link	pending
ex_322xcertificationofpfox.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20201231.htm	Edgar Link	pending
rvnc-20201231.xsd	Edgar Link	pending
rvnc-20201231_cal.xml	Edgar Link	unprocessable
rvnc-20201231_def.xml	Edgar Link	unprocessable
rvnc-20201231_g1.jpg	Edgar Link	pending
rvnc-20201231_g2.gif	Edgar Link	pending
rvnc-20201231_htm.xml	Edgar Link	completed
rvnc-20201231_lab.xml	Edgar Link	unprocessable
rvnc-20201231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2019 Q4 Form 10-K Financial Statement

#000147929021000057 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2019 Q4 Form 10-K Financial Statement

#000147929021000057 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc